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Dietary polyphenols may have a protective role against the development of CVD.Thus, we aimed to investigate the effects of green
coffee (GC), rich in chlorogenic acid, and black coffee (BC) on cardiovascular markers. A randomised pilot crossover study was
performed on healthy subjects who consumed both coffees for 2 weeks. We measured anthropometry, blood pressure, and arterial
elasticity after each intervention and collected urine samples tomonitor antioxidant capacity. Free cortisol and cortisone levels were
obtained from urine and analysed by specific ELISAmethods. Systolic blood pressure (𝑃 = 0.018) and arterial elasticity (𝑃 = 0.001)
were significantly reduced after GC. BMI (𝑃 = 0.04 for BC; 𝑃 = 0.01 for GC) and abdominal fat (𝑃 = 0.01 for BC; 𝑃 = 0.009
for GC) were also significantly reduced with no changes in energy intake. Urinary free cortisol was significantly reduced from
125.6±85.9 nmol/day to 76.0±54.9 nmol/day following GC and increased to 132.1±89.1 nmol/day after BC. Urinary free cortisone
increased by 18% following BC and 9% following GC (nonsignificant). Cortisol/cortisone ratio (indicating 11𝛽-HSD1 activity) was
reduced after GC (from 3.5 ± 1.9 to 1.7 ± 1.04, 𝑃 = 0.002). This suggests that GC can play a role in reducing cardiovascular risk
factors. Further research including hypertensive and overweight individuals will now be justified to clarify whether GC could have
a therapeutic role in CVD.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of mor-
tality and morbidity worldwide and there are several main
risk factors for its development which include dyslipidaemia,
smoking, diabetes, hypertension, and obesity [1]. Elevated
plasma glucocorticoid levels lead to an increase in abdominal
obesity and associated metabolic complications such as type
2 diabetes [2]. Cortisol is a steroid hormone (glucocorticoid)
secreted in response to stress and low blood cortisol levels
to restore homeostasis in the body [3]. In acute stress
catecholamines mobilise glucose and fatty acids to provide
the muscles and organs with enough energy for action and,
in this instance, glucocorticoids protect the body against
overreactions to stress. However, in chronic stress of food and
fluid deprivation, glucocorticoids stimulate gluconeogenesis
and increase the mobilisation of free fatty acids from subcu-
taneous and adipose tissues and amino acids from skeletal
muscle, which in the long term contribute to central obesity.
An association between cortisol and hypertension has also
been shown [4]. There are several mechanisms proposed by
which cortisol is thought to increase blood pressure (BP):
(i) it decreases the production and bioavailability of nitric
oxide (NO), which is a vasodilator [4]; (ii) it also increases
the responsiveness to vasoconstrictors such as the endothelin
(ET) system, which play an active role in the pathogenesis of
atherosclerosis [3], and stimulates sodium reabsorption in the
kidneys to preserve water [5].
Some authors reported that consumption of antioxidant-
rich foods and beverages has a protective role against the
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 482704, 9 pages
http://dx.doi.org/10.1155/2014/482704
2 BioMed Research International
development of risk factors for CVD [6]. Coffee, especially
green coffee (GC), is a known rich source of chlorogenic
acid (CGA), which is a type of polyphenol, and caffeine.
CGA is a phenolic compound with antioxidant activity [6]
and high bioavailability [7–9]. CGA may have antihyper-
tensive and weight reducing effects [10–12]. Both the blood
pressure and weight reducing effects have been attributed
to the inhibition of 11𝛽-hydroxysteroid dehydrogenase type
1 (11𝛽-HSD1) present in the adipose tissue and the liver
and involved in the conversion of the hormonally inactive
cortisone (11-dehydrocorticosterone in rodents) into active
cortisol (corticosterone in rodents) [10].Theweight loss effect
of CGA has also been associated with a reduction in the
absorption of glucose [10–12].
The composition of black coffee (BC) differs from that
of the green coffee due to the roasting process. As a result
their effects might also differ. BC may raise blood pressure,
identifying caffeine as the main BP-raising agent [13]. This
effect has been attributed to the stimulation of the sym-
pathetic nervous system, which in turn increases the rate
and force of cardiac contractility, leading to a temporary
increase in blood pressure [13]. In contrast, other studies
suggest that coffee might lower blood pressure due to a
development of tolerance to caffeine in regular coffee drinkers
[14, 15]. Habitual coffee consumption increases resting energy
expenditure by about 100 kcal/day, which in the long term
may lead to a significantweight loss [16, 17].Moreover, regular
intake of coffee encourages the excretion of Na and water and
the retention of K in the nephron [18], which may reduce BP.
Taking into consideration the health benefits attributed to
CGA from green coffee and the inconsistent findings regard-
ing the effects of black coffee, we aimed to (i) investigate
the effects of green coffee and black coffee in comparison to
baseline and (ii) compare the effects of green coffee and black
coffee on cardiovascular markers, including physiological
parameters (blood pressure and arterial elasticity), anthro-
pometry andbody composition (weight, waist circumference,
and abdominal fat), and glucocorticoids levels in healthy
volunteers.
2. Subjects and Methods
2.1. Study Population. The study protocol was approved by
the Queen Margaret University’s (QMU’s) Research Ethics
Committee in July 2011. The study was advertised in the
QMU website and interested volunteers were given detailed
information about the study. Eligibility criterion was assessed
using a health status questionnaire, which also asked about
physical activity habits. We included healthy subjects with
a BMI between 18 and 30 kg/m2 and no history of CVD,
including stroke, hypertension (WHO/ISH: SBP≥ 150mmHg
and DBP ≥ 90mmHg), coronary heart disease, and diabetes
mellitus. Those with a kidney condition or gastrointestinal
pathologies were all excluded. Smokers were excluded too
[8, 19]. All data collected from the volunteers was kept
anonymous and all measurements took place in the QMU
clinic room.
2.2. Study Design. We conducted a pilot study. Our design
was randomised and crossover, in which a repeated measure
design was also used. The randomisation was performed
using a software program (Clinstat, MS = DOS) by Martin
Bland [20], which is suitable for small scale trials. A printed
list of random allocations was obtained. Subjects were then
allocated into 2 groups; some were given the BC first and
others started on the GC. All measurements were taken
on three occasions: at baseline, after the black coffee, and
after the green coffee intervention. A week washout period
was allowed in between interventions to avoid a carryover
effect [21]. Volunteers completed a 2-day diet diary on
three occasions (at baseline and during each intervention)
including aweekend andweek day.The volunteers were asked
to follow their usual eating and physical activity patterns.
Questions about physical activity were asked at the start of
the study (baseline) and at the end of each intervention using
the same health status questionnaire. The diet diaries were
analysed usingWindiet 2005.The intervention period was 14
days for each arm of the study.
2.3. Coffee. The GC used in this project was Ethiopian
Harrar 4 (100%Arabica) and the BCwas Sainsbury’s Original
Blend Cafetie`re Coffee. The BC was a blend of Brazilian,
Colombian, Mexican, Nicaraguan, Peruvian, and Rwandan
beans. Subjects were asked to have 40 g of GC and BC per day
distributed throughout the day into four cups of coffee. This
ensured that high plasma coffee antioxidant concentrations
weremaintained over a period of time, allowing effects to take
place and the body to develop tolerance to caffeine, which can
take 2-3 days [13]. Although the amount of coffee given was
the same, GC contains 9% of water, which is higher than the
water content of BC, as this evaporates in the roasting process
[12].TheGCbeanswere grounded to powder using an electric
coffee grinder. Instructions on how to make the coffee were
provided and the Italian cafetie`re, the French cafetie`re, or the
filter coffee machine was used to prepare the coffee drinks.
2.4. Anthropometry and Body Composition Measurements.
Height (m) was measured using a leister-height scale and
weight (Kg) with a digital scale “Salter” model 9106. Mea-
surements were obtained using standard protocols and the
same equipment was employed every time to avoid inaccu-
racies between different scales. Body mass index (BMI) was
then calculated using the following standard equation: BMI
(Kg/m2) = (weight Kg/(height m)2). Upper percentage body
fat was measured using a Body Fat Monitor BF306 (Omron)
and waist circumference (cm) was taken following WHO
guidelines (2008) [22].
2.5. Blood Pressure and Arterial Elasticity Measurements.
A digital sphygmomanometer (Omron M5-I) was used to
measure BP while the subjects lied down comfortably in a
30-degree position and were allowed to relax for 10 minutes
in a quiet room to avoid “white coat” hypertension. The
pulsewave velocity (PWV)wasmeasured using a noninvasive
devise, Vicorder (Dell) equipment. To ensure reliability of
results; values were measured three times and mean was
calculated.
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Table 1: Concentration of total polyphenols and antioxidant capac-
ity determined in GC and BC as compared by the three methods of
coffee preparation.
10 g BC in 100mL water Filter Italian French
10 g GC in 100mL water Method Cafetie`re Cafetie`re
FRAP mMFeII (BC) 12.8 14.1 19.9
FRAP mMFeII (GC) 11.7 16.6 10.3
Polyphenols mg GAE (BC) 1451 1496 2475
Polyphenols mg GAE (GC) 1360 2052 972
Volunteers collected urine over 24-hour period on three
occasions: at baseline and at day 14 of each intervention. All
samples were consequently weighed and stored in sample
tubes in the freezer at −20∘C. The 24-hour urine collection
was evaluated in two ways: (i) by observing the urine output
at each stage of the intervention and then comparing the
three volumes obtained at the end and (ii) by monitoring
the creatinine of three random samples.The total polyphenol
content of these sampleswas analysed using Folin andCiocal-
teau’s method [23]. The method used to analyse the reducing
(antioxidant) capacity was Ferric ion reducing antioxidant
power (FRAP) [24]. The polyphenol concentration and
antioxidant capacity of the different coffee preparations were
analysed using the same methods and absorbance was mea-
sured using Sperk and Burke SB analytical spectrophotome-
ter (He𝜆ios 𝛼). Urinary cortisol and cortisone levels were
analysed by using indirect competitive sensitive and specific
ELISA methods according to the protocol devised by [25].
2.6. Statistical Analysis. All statistics were performed using
SPSS statistics version 17.0 and variables were first tested
for normal distribution. Nonparametric variables were trans-
formed to parametric using the log transformation option
and then analysed using a 2-tail paired 𝑡-test. Results are
expressed as mean ± standard error of mean (SEM). 𝑃 values
of ≤0.05 were considered significant.
3. Results
3.1. Subjects Characteristics. Twenty healthy volunteers par-
ticipated in this study (13 females and 7males) (Figure 2).One
volunteer dropped out and did not give a reason and another
completed only part of the study as the urine collection was
inconvenient. Therefore, 18 subjects completed the whole
intervention. All volunteers apart from two were moderate
regular coffee drinkers consuming 2–4 cups a day: 35% of the
research project population reported to be sedentary, while
the other 65% did regular exercise of at least 30-minute walk
a day.
3.2. Diet and Physical Activity. The phenolic and antioxi-
dant concentrations present in 10 g/100mL of green coffee
Ethiopian Harrar 4 (GC) and 10 g/100mL of Sainsbury’s
Original Blend Cafetie`re coffee (BC) are presented in Table 1.
Volunteers used a mixture of methods during the interven-
tion.
Volunteers were asked at the end of each intervention
to report any dosage missed and compliance was calculated
accordingly. Subjects had an estimated mean compliance of
94.5% for the GC, with only one subject missing a day dosage
of GC. While for the BC there was 92% compliance with a
maximum dosage missed of one and a half days.
As it can be seen from Table 2, the total energy intake
and sodium intake reported from the diet diaries did not
significantly differ between baseline and each intervention.
Finally, all volunteers reported in the health status question-
naire having maintained their physical activity throughout
the whole study.
3.3. Effect on PhysiologicalMarkers. GC significantly reduced
systolic BP (𝑃 = 0.02) by mean ± SEM 2.65 ± 1.37mmHg
compared to baseline. BC reduced systolic BP by 2.23 ±
1.44mmHg, but this was not significant. No statistical signif-
icant difference was found when the two interventions were
compared against each other. Diastolic BP was significantly
reduced after both interventions: 2.9 ± 1.05mmHg after BC
and 3.1 ± 0.81 after GC, and the comparison between the two
interventions was not significant (Table 2).
Finally PWV mean values also decreased by 0.20 ±
0.12m/second following BC intake and by 0.26 ±
0.12m/second after GC, only significant after GC (𝑃 =
0.001). No significant difference was obtained between BC
and GC (𝑃 = 0.49) (Table 3).
3.4. Effect on Biochemical Markers. No significant difference
was seen in the antioxidants’ capacity and polyphenol con-
centration from the urine samples. Cortisol levels decreased
significantly by 39% after the GC intervention and increased
by 5% after BC (there was a significant difference between
interventions). While cortisone levels were 18% and 9%
higher following BC and GC intervention, respectively, this
was not significant. BC and GC significantly reduced 24-
hour urinary free cortisol/cortisone ratio and there was
a significant difference when the two interventions were
compared (𝑃 = 0.02; Figures 3 and 4; Table 3).
3.5. Effect on Anthropometrical Measurements. At baseline,
the participant’s weight and BMI were 70.52 ± 15.89 kg and
24.23 ± 4.6 kg/m2, respectively. This was only significantly
reduced after GC (𝑃 = 0.01 for both parameters) to 69.13 ±
15.9 kg and 23.95 ± 4.78 kg/m2, respectively.
Waist circumference decreased by an average of 0.89 cm
after the BC intervention and 1.74 cm after the GC intake
compared to baseline. Abdominal fat decreased by an average
of 1.44% (BC) and 1.75% (GC). Both were significantly
reduced after each intervention (WC: 𝑃 = 0.04 (BC) and
𝑃 = 0.009 (GC); abdominal fat: 𝑃 = 0.01 (BC) and 𝑃 = 0.015
(GC)).No significant differencewas seen betweenBCandGC
in either of the two anthropometrical parameters (𝑃 = 0.9)
(see Table 4). There were no significant differences observed
in energy and sodium intake at baseline and at the end of both
interventions.
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Table 2: Effect of black coffee (BC) and green coffee (GC) on physiological markers, total polyphenols, and antioxidant capacity (FRAP) in
24-hour urine samples (mean ± SEM).
Study population Baseline BC Baseline versus BC (95% CI) GC Baseline versus GC (95% CI)
SBP (mmHg) 116.9 ± 2.4 114.5 ± 2.5 −0.81 to 5.27 113.5 ± 3.11 1.2 to 5.5
DBP (mmHg) 74.0 ± 1.7 71.2 ± 1.72 0.77 to 5.20 71.2 ± 2.23 1.4 to 4.8
PWV (m/sec) 6.63 ± 0.20 6.40 ± 0.20 −0.04 to 0.44 6.29 ± 0.304 0.2 to 0.5
Total polyphenols (mgGAE/day) 523 ± 33 597 ± 44 −175 to 27 547.78 ± 36.4 −156 to 106
FRAP (mMFeII/day) 7.22 ± 3.38 8.85 ± 4.53 −3.5 to 0.4 7.21 ± 3.33 −1.7 to 2.5
Energy intake (kcal) 1807 ± 29 1903 ± 31 −328 to 164 1853 ± 29 −245 to 113
Sodium intake (mg) 2571 ± 277 2609 ± 291 −429 to 675 2490 ± 277 −268 to 719
Potassium intake (mg) 2681 ± 190 3310 ± 238 −869 to −1182 3161 ± 276 −933 to 233
BC: black coffee; GC: green coffee; SBP: systolic blood pressure, DBP: diastolic blood pressure; PWV: pulse wave velocity; CI: 95% confidence interval;
significance expressed as 𝑃 ≤ 0.05; 2-tail paired 𝑡-test; 1baseline versus GC, 𝑃 = 0.02; 2baseline versus BC, 𝑃 = 0.01; 3baseline versus GC, 𝑃 = 0.001; 4baseline
versus GC, 𝑃 = 0.001.
Table 3: Comparison of results obtained (mean ± SEM) after 14 days of green coffee and black coffee intervention.
Study population Black coffee Green coffee Difference 95% CI 𝑃
BMI (kg/m2) 23.9 ± 1.1 23.9 ± 1.1 0.0 −0.21 to 0.22 0.9
Waist Circumference (cm) 79.2 ± 3.3 79.1 ± 3.4 0.1 −0.53 to 0.67 0.8
Abdominal fat (%) 28.9 ± 1.9 28.4 ± 2.0 0.5 −0.13 to 1.18 0.1
SBP mmHg 114.5 ± 11.2 113.5 ± 13.3 1.0 −11.43 to 7.76 0.6
DBP mmHg 71.2 ± 7.6 71.2 ± 9.9 0.0 −9.32 to 5.75 0.5
PWVm/sec 6.4 ± 0.9 6.3 ± 1.2 0.1 −0.55 to 0.33 0.5
Polyphenol (mgGAE/day) 597 ± 241 548 ± 211 49.0 −55.11 to 153.95 0.3
Antioxidant (mMFeII/day) 8.8 ± 4.5 7.2 ± 3.3 1.6 −0.30 to 4.14 0.08
Energy intake (kcal) 1880 ± 147 1863 ± 128 17.0 −256 to 291 0.9
Sodium intake (mg) 2609 ± 291 2490 ± 277 119.0 −228 to 467 0.5
Potassium intake (mg) 3310 ± 238 3161 ± 276 149.0 −304 to 602 0.5
Urinary free F (nmol/day)∗ 114.5 ± 331.7 68.4 ± 64.6 46.1 12.4 to 93.7 0.01
Urinary free E (nmol/day)∗ 40.9 ± 36.6 47.7 ± 26.5 −6.8 −6.26 to 15.8 0.5
Urinary F : E ratio (nmol/day) 2.55 ± 2.58 1.53 ± 1.42 1.02 0.14 to 1.78 0.02
95% CI: 95% confidence interval; 𝑃 values are from paired 𝑡-test. ∗Variables normalised using the log 10 (SPSS 17.0). F: cortisol; E: cortisone.
3.6. Adverse Events. One volunteer reported feeling “a bit
dizzy” and “nauseous” immediately after ingesting the GC
and another reported an increase in libido. The first one was
linked to the substantial reduction in BP that volunteer had.
No other adverse effects were reported or noted during or
after the interventions.
4. Discussion
The results from our pilot study showed that consumption
of green coffee significantly improved arterial elasticity and
reduced systolic and diastolic blood pressure in the healthy
cohort included in the study. Black coffee also lowered systolic
and diastolic blood pressure, but only the latter was statisti-
cally significant. Additionally, the results demonstrated that
consumption of both coffees for two weeks, during which
subjects did not modify their diet and physical activity, led to
a significant reduction in body weight, waist circumference,
and % abdominal fat. There was a significant decrease in the
stress hormone urinary free cortisol levels only after GC, and
urinary free cortisone (inactive form) levels increased slightly
after both interventions. The ratio cortisol/cortisone was sig-
nificantly reduced following both BC and GC consumption
indicating that coffee intake may inhibit 11𝛽HSD1 enzyme
activity. However, there was no significant change in either
the total urinary polyphenol concentration or the antioxidant
capacity after interventions.
4.1. Blood Pressure and Arterial Elasticity. The guidelines
issued by NICE (2006) stated that the risk associated with
increasing BP is continuing [1]. Each 2mmHg rise in systolic
BP is associated with a 7% increased risk of mortality
from ischaemic heart disease and 10% from stroke [1].
The blood pressure lowering effects of GC reported in this
study of 2.65 ± 1.37mmHg for systolic BP and 3.10 ±
0.81mmHg for diastolic BP in normotensive individuals may
also reduce blood pressure in hypertensive individuals. The
effects reported in our study are corroborated by others
[10, 25]. Kozuma et al. [10] demonstrated a reduction in
systolic BP of 5mmHg and in diastolic BP of 4.7mmHg in
mildly hypertensive individuals after the ingestion of green
coffee bean extract (GCBE) over a period of 28 days and a
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Table 4: Characteristics of population after 14 days of black coffee and green coffee intake expressed as mean ± SEM.
Study population Baseline BC Baseline versus BC (95% CI) GC Baseline versus GC (95% CI)
BMI (kg/m2) 24.3 ± 1.0 23.9 ± 1.11 0.01 to 0.40 23.9 ± 1.12 0.05 to 0.30
Weight (Kg) 70.8 ± 3.5 69.3 ± 3.5 −0.10 to 0.80 69.1 ± 3.53 0.20 to 0.90
Waist circumference (cm) 80.8 ± 3.2 79.2 ± 3.34 0.08 to 1.80 79.1 ± 3.45 0.30 to 1.80
Abdominal fat (%) 30.1 ± 1.9 28.9 ± 2.06 0.20 to 2.80 28.4 ± 2.07 0.39 to 3.30
BC: black coffee; GC: green coffee; BMI: body mass index; 95% CI: 95% confidence intervals; 2-tail paired 𝑡-test, significance expressed as 𝑃 ≤ 0.05; 1B versus
BC, 𝑃 = 0.04; 2B versus GC, 𝑃 = 0.01; 3B versus GC, 𝑃 = 0.006; 4B versus BC, 𝑃 = 0.0.03; 5B versus GC, 𝑃 = 0.009; 6B versus BC, 𝑃 = 0.02; 7B versus GC,
𝑃 = 0.01.
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Figure 1: Inhibition of glucose-6-phosphate by chlorogenic acid. CGA is involved in blocking the uptake of glucose-6-phosphate by inhibiting
glucose-6-phosphate translocase. This prevents the enzyme glucose-6-phosphate dehydrogenase from providing NADPH as a cofactor for
the reductase activity and so the conversion of cortisone to cortisol is inhibited. NADPH: nicotinamide adenine dinucleotide phosphate.
Adapted from a Ph.D. thesis by Al Moosawi, Queen Margaret University, 2010 [42].
dose of 93mg/day. Almoosawi et al. [26] meanwhile found a
significant reduction in systolic BP after testing the effects of
GCBE for 2 weeks in 13 overweight volunteers. In contrast,
Watanabe et al. [27] did not find any significant changes
in a 4-month study performed using normotensive male
individuals, even though an average reduction of 4.6mmHg
(SBP) and 3.2mmHg (DBP) was observed at the end of the
intervention period, which might have been due to the small
sample size.
Previous research showed an association between habit-
ual coffee intake and an increase in arterial elasticity [9].
Habitual coffee consumption had an inverse association with
surface leukocyte adhesion molecules (E-selectin) and C-
reactive protein in healthy and diabetic women, which in turn
improved arterial stiffness. This was attributed to the strong
antioxidant capacity present in coffee [9]. Our study only
found a significant reduction in PWV following GC inter-
vention. Yet a significant difference in neither the polyphenol
concentration nor the antioxidant capacitywas obtained.This
raises the question of why there was an improvement in
arterial elasticity without changes in the antioxidant capacity
and why the BP lowering effect from GC was more potent
than that of BC.
It is well established that high cortisol levels contribute
to hypertension by overstimulation of the hypothalamic
adrenal axis and sympathetic nervous system [28] and
those individuals appear to have higher levels of urinary
free cortisol and catecholamines metabolites. Our results
illustrate a decrease in 24-hour urinary free cortisol, the
cortisol/cortisone ratio, and the BP afterGC. Catecholamine’s
metabolites were not analysed. Thus, our hypothesis is that
chlorogenic acid present mainly in GC has an inhibitory
effect on the enzyme 11-𝛽HSD1 (Figure 1), whilst the active
BC compound produced during the roasting process has a
stimulant effect on 11-𝛽HSD2 [29]. In addition, the inhibitory
effect on the enzyme 11𝛽-HSD1 is 7–10-fold higher than the
11𝛽-HSD2, which may explain the higher effect of GC on the
urinary free cortisol/cortisone ratio. Secondly, cortisol might
reduce the production and bioavailability of vasodilators such
as nitric oxide [30]. Thus, a reduction of cortisol levels may
have led to an improvement in arterial elasticity and BP.
A reduction in both PWV and BP is not entirely sur-
prising since they are intrinsically related. The pulse wave
generated by the contraction of the left ventricle travels
towards the periphery where a part of it is reflected back
[19]. In elastic arteries, this wave returns travelling slowly and
arrives during diastole facilitating then coronary perfusion
[19]. With arterial stiffness this wave arrives early, before the
aortic valve closes, increasing therefore SBP or the pressure
that the left ventricle needs to propel the blood to reach the
peripheral vessels [19].
Results concerning the effects of black coffee intake on
BP and PWV are still inconsistent. Our study showed a
significant reduction in diastolic BP only. Although, both
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20 healthy volunteers
Baseline measurements
10 subjects
1 dropout
Roasted (black) coffee
↓
Measurements
10 subjects
1 dropout
Green coffee
↓
Measurements
9 subjects
Green coffee
↓
Measurements
9 subjects
Roasted (black) coffee
↓
Measurements
1-week washout
2 weeks
2 weeks
Total duration of trial: 35 days
Figure 2: Flow diagram of our crossover study protocol and sample size.
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Figure 3: Urinary free cortisol and cortisone levels (nmole/24
hours) obtained before and after consumption of green and black
coffees. Results are expressed as mean ± SEM; ∗𝑃 = 0.01 after
Wilcoxon test.
systolic BP and PWV were reduced, neither was significant.
This may be attributed to the following: (i) the characteristics
of our volunteers, as 18 out 20 were regular coffee consumers
[9, 14, 31–35], findings not seen in nonregular coffee con-
sumers [9, 14]; (ii) the diuretic properties of coffee [36, 37]
brought by the inhibition of plasma renin activity [36, 37]
and the high concentrations of potassium present in coffee,
also seen in the significant increase in potassium intake of
our volunteers (Table 3) [14]. Consequently, the presence of
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Ra
tio
 co
rt
iso
l/c
or
tis
on
e
Baseline BC GC
∗
∗∗
Figure 4:Urinary free cortisol/cortisone ratio levels obtained before
and after consumption of black and green coffee. Results expressed
as 24 h mean ± SEM. There was a significant reduction in urinary
free cortisol/cortisone ratio after consumption of black coffee (∗𝑃 =
0.04) and green coffee (∗∗𝑃 = 0.003).
both CGA in green coffee and CGA metabolites, as well as
the high concentrations of potassium [14], could be the agents
that neutralise the effects of caffeine and have the lowering
effects of BP seen in our cohort.
4.2. Weight, Waist Circumference, and Abdominal Fat. This
study has shown that BMI fell following the two interven-
tions; however, this was only significant following GC intake.
Both coffees significantly reduced abdominal fat despite
energy intake and physical activity remaining the same
throughout the intervention.
The effect of GC in reducing body weight is supported by
others [21]. The author of [21] reported a significant weight
loss of 5.4 kg after 12 weeks of Coffee Slender intake only;
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however, the sample sizewas also small [15]. In contrast to our
findings, a prospective cohort study involving subjects aged
32–88 years showed an association between BC consumption
and weight reduction [38]. The weight lowering effect of
green coffee has been attributed to the effects of CGA [21,
39]. CGA can reduce and slow down the uptake of glucose
in the small intestine and caffeine increases resting energy
expenditure [21, 39]. Perhaps the difference between the two
interventions is explained by the fact that the concentrations
of both CGA and caffeine are different, being both higher in
GC. CGA slows down the absorption of glucose in the small
intestine and it was thought to inhibit fat accumulation in the
abdominal area and caffeine is known to increase lipolysis
and total energy expenditure. Furthermore, CGA is known
to inhibit 11𝛽-HSD 1 and 2 activity. This could also be the
cause of the reduction in urinary free cortisol levels seen in
this study, which in turn may have led to the reduction in BP
and the improvement in arterial elasticity.
Finally, the waist circumference and abdominal obesity
reduction shown in this study, especially following GC,
supports the hypothesis that a decrease in visceral adiposity
occurred as a result of the inhibition of 11𝛽-HSD1 expression
by CGA that was evident by the reduction of urinary free
cortisol/cortisone ratio after both interventions.
There are a number of limitations in this study. We
acknowledge that the sample size of our study is relatively
small and that the age range is [25–41], which makes the
extrapolation to the general or specific population difficult;
nevertheless, all volunteers were healthy and further research
will now be justified to investigate these findings using a
larger sample and more specific populations. Accuracy of the
Body Fat Monitor BF306 (Omron) has been argued as the
reported error of measurement is 4.1% which might have led
to errors in assessing the percentage (%) abdominal adiposity.
However, the waist circumference was also measured, and
both measurements were in agreement, which allowed the
validation of the results obtained in this study. Although,
the activity of 11𝛽-HSD1 and 11𝛽-HSD2 were not directly
measured, 24-hour urinary collection was obtained from the
volunteers and compliance was evaluated, allowing the anal-
ysis of both cortisol and cortisone levels and the consequent
calculation of their secretion ratio, which in turn can assess
the activity of the enzyme. Additionally, the volunteers were
asked to follow similar physical activity and eating patterns
during the two interventions, but diet diaries were only
recorded for two days on three occasions and might not
represent the intake of the whole intervention. Also, we used
questionnaires to assess whether volunteers maintained their
usual physical activity patterns, which might have not been a
true representation. Finally, our study was not blinded, which
may have led to bias, and the possibility of significant findings
by chancemay have occurred due to bothmultiple testing and
changes that occur over time when participating in trial.
5. Conclusion
This pilot study proposes that coffee intake, especially GC,
might have a role to play in the reduction of cardiovascular
risk factors and perhaps CVD in the long term. Further
research (including blinded clinical trials, although this
might be difficult) using a larger sample of hypertensive and
overweight individuals, as well as longer intervention period,
is warranted to clarify whether GC could have a preventative
or a therapeutic role in the fight against CVD.
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